PROPHESYS is a large, multinational, non-interventional prospective cohort study of chronic hepatitis C patients treated with peginterferon alfa/ribavirin. This subanalysis assesses rates of premature treatment discontinuation stratified by on-treatment virological response (VR).

Methods

This PROPHESYS subanalysis is restricted to treatment-naive, hepatitis C virus (HCV) genotype (G)1/2/3 mono-infected patients who received peginterferon alfa-2a (40KD)/ribavirin with intended treatment duration of 48 (G1) or 24 weeks (G2/3). Early virological responses were classified into four mutually exclusive categories [rapid VR (RVR), complete early VR (cEVR), partial EVR (pEVR), no RVR/EVR], using standard criteria.

Results

The likelihood for shortening treatment owing to good efficacy was highest among patients with an RVR and HCV RNA ≤400 000 IU/ml (G1 10.0%; G2/3 5.8%) whereas for poor efficacy, it was highest in G1 non-RVR/EVR patients with HCV RNA >400 000 IU/ml (56.6%). Factors significantly associated with early treatment discontinuation as a result of good efficacy in G1 patients included RVR vs. no RVR/EVR and, at baseline, lower HCV RNA, lower FIB-4 score, HCV infection via injection drug use. For G2/3 patients, factors included lower baseline HCV RNA and G2 vs. G3 infection. Most patients started with the recommended peginterferon alfa-2a dose, but a high proportion received a higher-than-recommended ribavirin dose.

Conclusions

Despite international guidelines, few physicians used early viral kinetics to abbreviate treatment. Therefore, relatively few patients with an RVR and low baseline HCV RNA abbreviated treatment. In addition, there were deviations in ribavirin starting doses, suggesting that physicians tailor treatment according to local guidelines or previous experience.

References

1 European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245–64.
10.1016/j.jhep.2011.02.023
PubMed Web of Science® Google Scholar
2Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chroninc hepatitis C virus infection. J Hepatol 2011; 55: 69–75.
10.1016/j.jhep.2010.10.032
PubMed Web of Science® Google Scholar
3Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012; 56: 2039–50.
10.1002/hep.25892
CAS PubMed Web of Science® Google Scholar
4Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55.
10.7326/0003-4819-140-5-200403020-00010
CAS PubMed Web of Science® Google Scholar
5Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
10.1056/NEJMoa020047
CAS PubMed Web of Science® Google Scholar
6Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–74.
10.1002/hep.22759
CAS PubMed Web of Science® Google Scholar
7Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients. Gastroenterology 2010; 139: 120–9.
10.1053/j.gastro.2010.04.013
CAS PubMed Web of Science® Google Scholar
8Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425–33.
10.1016/j.jhep.2005.04.009
CAS PubMed Web of Science® Google Scholar
9Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47: 43–50.
10.1002/hep.22061
CAS PubMed Web of Science® Google Scholar
10Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609–17.
10.1056/NEJMoa042608
CAS PubMed Web of Science® Google Scholar
11Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124–34.
10.1056/NEJMoa066403
CAS PubMed Web of Science® Google Scholar
12Lee SS, Sherman M, Ramji A, et al. Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. Aliment Pharmacol Ther 2012; 35: 37–47.
10.1111/j.1365-2036.2011.04911.x
CAS PubMed Web of Science® Google Scholar
13Sarrazin C, Schwendy S, Moller B, et al. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24–72 weeks. Gastroenterology 2011; 141: 1656–64.
10.1053/j.gastro.2011.07.019
CAS PubMed Web of Science® Google Scholar
14 European Medicines Agency. Pegasys summary of product characteristics, revised 2010. Available from: http://www.ema europa eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000395/WC500039195 pdf.
Google Scholar
15 Genetech USA. Pegasys full prescribing information and medication guide. Available from: http://www.gene.com/gene/products/information/pegasys/pdf/pi.pdf.
Google Scholar
16Cline DM, Welch KJ, Cline LS, Brown CK. Physician compliance with advanced cardiac life support guidelines. Ann Emerg Med 1995; 25: 52–7.
10.1016/S0196-0644(95)70355-1
CAS PubMed Web of Science® Google Scholar
17Worrall G, Freake D, Kelland J, Pickle A, Keenan T. Care of patients with type II diabetes: a study of family physicians' compliance with clinical practice guidelines. J Fam Pract 1997; 44: 374–81.
CAS PubMed Web of Science® Google Scholar
18Craig TJ. Assessment of care of patients with asthma in a family practice training program. J Am Osteopath Assoc 1996; 96: 305–8.
10.7556/jaoa.1996.96.5.305
CAS PubMed Google Scholar
19Lugtenberg M, Zegers-van Schaick JM, Westert GP, Burgers JS. Why don't physicians adhere to guideline recommendations in practice? An analysis of barriers among Dutch general practitioners Implement Sci 2009; 4: 54.
10.1186/1748-5908-4-54
PubMed Web of Science® Google Scholar
20Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement JAMA 1999; 282: 1458–65.
10.1001/jama.282.15.1458
CAS PubMed Web of Science® Google Scholar
21McGlynn EA, Asch SM, Adams J, et al. The Quality of Health Care Delivered to Adults in the United States. N Engl J Med 2003; 348: 2635–45.
10.1056/NEJMsa022615
PubMed Web of Science® Google Scholar
22Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207–17.
10.1056/NEJMoa1009482
CAS PubMed Web of Science® Google Scholar
23Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–16.
10.1056/NEJMoa1012912
CAS PubMed Web of Science® Google Scholar
24Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014–24.
10.1056/NEJMoa1014463
CAS PubMed Web of Science® Google Scholar
25Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417–28.
10.1056/NEJMoa1013086
CAS PubMed Web of Science® Google Scholar
26Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433–44.
10.1002/hep.24641
PubMed Web of Science® Google Scholar
27Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, et al. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin. J Viral Hepat 2012; 19: 766–74.
10.1111/j.1365-2893.2012.01624.x
CAS PubMed Web of Science® Google Scholar
28Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317–25.
10.1002/hep.21178
CAS PubMed Web of Science® Google Scholar
29Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954–60.
10.1002/hep.21159
CAS PubMed Web of Science® Google Scholar
30Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451–8.
10.1053/j.gastro.2008.04.015
CAS PubMed Web of Science® Google Scholar
31Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97–103.
10.1016/j.jhep.2005.10.003
CAS PubMed Web of Science® Google Scholar
32Diago M, Shiffman ML, Bronowicki J, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2010; 51: 1897–3.
10.1002/hep.23531
CAS PubMed Google Scholar
33Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007; 21: 25C–34C.
10.1155/2007/138245
PubMed Google Scholar
34 Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 615–33.
10.1111/j.1440-1746.2007.04883.x
CAS PubMed Google Scholar
35Slavenburg S, Lamers MH, Roomer R, et al. Current clinical care compared with new Dutch guidelines for hepatitis C treatment. Neth J Med 2009; 67: 177–81.
CAS PubMed Web of Science® Google Scholar
36Leroy V, Serfaty L, Bourliere M, et al. Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French association for the study of the Liver. Liver Int 2012; 32: 1477–92.
10.1111/j.1478-3231.2012.02856.x
CAS PubMed Web of Science® Google Scholar
37 National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. 2010. Available from: http://www.nice.org.uk/nicemedia/live/13180/50856/50856.pdf.
Google Scholar
38Mangia A, Dalgard O, Minerva N, et al. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Aliment Pharmacol Ther 2010; 31: 1346–53.
10.1111/j.1365-2036.2010.04290.x
CAS PubMed Web of Science® Google Scholar
39Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275–9.
10.1002/hep.20563
CAS PubMed Web of Science® Google Scholar
40Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 371–9.
10.1002/hep.21712
CAS PubMed Web of Science® Google Scholar
41Cheinquer H, Shiffman ML, Zeuzem S, et al. The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study. Hepatology 2012; S1: 271A.
Google Scholar

Citing Literature

Volume34, Issue7

August 2014

Pages e217-e228

In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions

Abstract

Background & Aims

Methods

Results

Conclusions

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions

Abstract

Background & Aims

Methods

Results

Conclusions

References

Citing Literature

References

Related

Information